The MRNA stock price fluctuated between $409.66 and $493.76 throughout the trading session with the volume trading being 42M shares, which represented a positive variation when compared to the three months average volume of 13M shares.
The share price of Moderna, Inc. (NasdaqGS:MRNA) ran up 17.1% to close Monday’s market session at $484.47, higher as compared to yesterday’s close which brings the market valuation of the company to $166.12B.
The 52-week high for the Moderna, Inc.’s shares is $443.99. This is the highest price the MRNA shares have gotten with a massive since the share price dropped to a 52-week low of $54.21.
The company currently has a 277.29 P/E ratio and a price target of $184.92.
What does the trading volume tell us about the MRNA stock?
During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen growth in its daily volume. The daily volume was of 13M, while in the last 10 days the average was 20.36M and last three months – 13.23M.
The increasing interest in the MRNA stock from the investors is helping to drive the stock price up.
Shrinking short interest
The Moderna, Inc.’s shares are seeing a decreasing short interest compared to the previous month. As of today, there are 11.83M shares being shorted which translates into 1.27 of a short ratio for MRNA, while in the previous month the shorted shares were 12.94M.
Moderna, Inc.’s (NasdaqGS:MRNA) financials
With a market cap of 166.12B, Moderna, Inc. holds a total cash of $7.74B that translates into $19.26 per share, while the total debt is of $279M.
The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 24,112.50%. The current revenue is of $2.73B that is $6.95 per share.
This is a not so good sign for the future.